Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Revisiting complete response in light chain amyloidosis.

Sidana S, Dispenzieri A, Murray DL, Go RS, Buadi FK, Lacy MQ, Gonsalves WI, Dingli D, Warsame R, Kourelis T, Muchtar E, Hayman SR, Kapoor P, Kyle RA, Leung N, Rajkumar SV, Gertz MA, Kumar SK.

Leukemia. 2019 Nov 26. doi: 10.1038/s41375-019-0664-9. [Epub ahead of print] No abstract available.

PMID:
31772296
2.

Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.

Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Lisa Hwa Y, Gonsalves W, Warsame R, Russell S, Lust JA, Lin Y, Zeldenrust S, Rajkumar SV, Kyle RA, Kumar SK, Dispenzieri A.

Leukemia. 2019 Nov 22. doi: 10.1038/s41375-019-0655-x. [Epub ahead of print]

PMID:
31758090
3.

Association between facility volume and mortality of patients with classic Hodgkin lymphoma.

Goyal G, Tella SH, Funni S, Kommalapati A, Inselman JW, Shah ND, Go RS, Ansell SM.

Cancer. 2019 Nov 12. doi: 10.1002/cncr.32584. [Epub ahead of print]

PMID:
31714588
4.

Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population.

Durani U, Asante D, Halfdanarson T, Heien HC, Sangaralingham L, Thompson CA, Peethambaram P, Quevedo FJ, Go RS.

J Natl Compr Canc Netw. 2019 Nov 1;17(11):1355-1361. doi: 10.6004/jnccn.2019.7315.

PMID:
31693982
5.

Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy.

Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui M, Zeldenrust S, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI.

Clin Lymphoma Myeloma Leuk. 2019 Oct 9. pii: S2152-2650(19)32011-7. doi: 10.1016/j.clml.2019.09.624. [Epub ahead of print]

PMID:
31685378
6.

Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms.

Goyal G, Ravindran A, Liu Y, He R, Shah MV, Bennani NN, Patnaik MM, Rech KL, Go RS; Mayo Clinic Hisiocytosis Working Group.

Haematologica. 2019 Oct 17. pii: haematol.2019.234187. doi: 10.3324/haematol.2019.234187. [Epub ahead of print]

7.

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.

Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Am J Hematol. 2020 Jan;95(1):4-9. doi: 10.1002/ajh.25657. Epub 2019 Oct 29.

PMID:
31612526
8.

Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer.

Duma N, Idossa DW, Durani U, Frank RD, Paludo J, Westin G, Lou Y, Mansfield AS, Adjei AA, Go RS, Ailawadhi S.

Clin Lung Cancer. 2019 Aug 30. pii: S1525-7304(19)30254-2. doi: 10.1016/j.cllc.2019.08.005. [Epub ahead of print]

PMID:
31570228
9.

Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.

Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Amyloid. 2019 Sep 23:1-4. doi: 10.1080/13506129.2019.1666709. [Epub ahead of print]

PMID:
31544536
10.

Association between anemia and hematological indices with mortality among cardiac intensive care unit patients.

Rayes HA, Vallabhajosyula S, Barsness GW, Anavekar NS, Go RS, Patnaik MS, Kashani KB, Jentzer JC.

Clin Res Cardiol. 2019 Sep 18. doi: 10.1007/s00392-019-01549-0. [Epub ahead of print]

PMID:
31535171
11.

Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin.

Goyal G, Liu Y, Ravindran A, Al-Kali A, Go RS, Patnaik MM, Rech KL; Mayo Clinic Histiocytosis Working Group.

Br J Haematol. 2019 Oct;187(2):e51-e54. doi: 10.1111/bjh.16177. Epub 2019 Sep 2. No abstract available.

PMID:
31475353
12.

The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease.

Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Davidge-Pitts CJ, Hurtado MD, Ravindran A, Sartori Valinotti JC, Bennani NN, Shah MV, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Mayo Clin Proc. 2019 Oct;94(10):2054-2071. doi: 10.1016/j.mayocp.2019.02.023. Epub 2019 Aug 28. Review.

PMID:
31472931
13.

Etiologies of Extreme Thrombocytosis: A Contemporary Series.

Hsieh RW, Ravindran A, Hook CC, Begna KH, Ashrani AA, Pruthi RK, Marshall AL, Hogan W, Litzow M, Hoyer J, Oliveira JL, Vishnu P, Call TG, Al-Kali A, Patnaik M, Gangat N, Pardanani A, Tefferi A, Go RS.

Mayo Clin Proc. 2019 Aug;94(8):1542-1550. doi: 10.1016/j.mayocp.2019.01.041.

PMID:
31378229
14.

Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013.

Al-Kali A, Zblewski D, Foran JM, Patnaik MS, Larrabee BR, Gangat N, Begna KH, Elliott MA, Hogan WJ, Tefferi A, Litzow MR, Go RS.

Mayo Clin Proc. 2019 Aug;94(8):1467-1474. doi: 10.1016/j.mayocp.2019.02.029.

PMID:
31378228
15.

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Amyloid. 2019;26(sup1):101-102. doi: 10.1080/13506129.2019.1582486. No abstract available.

PMID:
31343331
16.

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.

Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Br J Haematol. 2019 Dec;187(5):588-594. doi: 10.1111/bjh.16096. Epub 2019 Jul 12.

PMID:
31298751
17.

Postsurgical thrombotic microangiopathy: Case series and review of the literature.

Sridharan M, Hook CC, Leung N, Winters JL, Go RS; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group.

Eur J Haematol. 2019 Oct;103(4):307-318. doi: 10.1111/ejh.13284. Epub 2019 Jul 23.

PMID:
31251415
18.

Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis.

Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, Paludo J.

Cancer. 2019 Oct 15;125(20):3574-3581. doi: 10.1002/cncr.32357. Epub 2019 Jun 28.

PMID:
31251390
19.

Impact of acquired del(17p) in multiple myeloma.

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Adv. 2019 Jul 9;3(13):1930-1938. doi: 10.1182/bloodadvances.2018028530.

20.

Erdheim-Chester Disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1.

Razanamahery J, Diamond EL, Cohen-Aubart F, Plate KH, Lourida G, Charlotte F, Hélias-Rodzewicz Z, Goyal G, Go RS, Dogan A, Abdel-Wahab O, Durham B, Ozkaya N, Amoura Z, Emile JF, Haroche J.

Haematologica. 2019 May 23. pii: haematol.2019.216937. doi: 10.3324/haematol.2019.216937. [Epub ahead of print]

21.

Erdheim-Chester disease: expanding the spectrum of cutaneous manifestations.

Kobic A, Shah KK, Schmitt AR, Goyal G, Go RS, Guo R, Rech KL, Sartori-Valinotti JC; Mayo Clinic Histiocytosis Working Group.

Br J Dermatol. 2019 May 23. doi: 10.1111/bjd.18153. [Epub ahead of print]

PMID:
31120137
22.

Improved Interpretability of Machine Learning Model Using Unsupervised Clustering: Predicting Time to First Treatment in Chronic Lymphocytic Leukemia.

Chen D, Goyal G, Go RS, Parikh SA, Ngufor CG.

JCO Clin Cancer Inform. 2019 May;3:1-11. doi: 10.1200/CCI.18.00137.

23.

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Leuk Lymphoma. 2019 Dec;60(12):2960-2967. doi: 10.1080/10428194.2019.1613536. Epub 2019 May 16.

PMID:
31096812
24.

Cardiac prostheses-related hemolytic anemia.

Alkhouli M, Farooq A, Go RS, Balla S, Berzingi C.

Clin Cardiol. 2019 Jul;42(7):692-700. doi: 10.1002/clc.23191. Epub 2019 May 6. Review.

25.

Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States.

Tella SH, Kommalapati A, Rech KL, Go RS, Goyal G.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):441-446. doi: 10.1016/j.clml.2019.03.026. Epub 2019 Apr 1.

PMID:
31005630
26.

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Haematologica. 2019 Apr 19. pii: haematol.2019.219626. doi: 10.3324/haematol.2019.219626. [Epub ahead of print]

27.

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.

Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2019 Apr 23;3(8):1226-1229. doi: 10.1182/bloodadvances.2019032458.

28.

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.

Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2019 Jul;94(7):751-756. doi: 10.1002/ajh.25481. Epub 2019 Apr 30.

PMID:
30945330
29.

Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.

Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS, McWilliams RR, Mahipal A.

Eur J Surg Oncol. 2019 Aug;45(8):1432-1438. doi: 10.1016/j.ejso.2019.03.023. Epub 2019 Mar 21.

PMID:
30914290
30.

Patterns and utility of vitamin B12 and folate testing in patients with isolated thrombocytopenia.

DeLoughery EP, Ravindran A, Ashrani AA, Begna KH, Hook CC, Marshall AL, Pruthi RK, Wolanskyj-Spinner AP, Go RS.

Ann Hematol. 2019 Aug;98(8):1993-1994. doi: 10.1007/s00277-019-03666-2. Epub 2019 Mar 15. No abstract available.

PMID:
30877374
31.

Natural history of multiple myeloma with de novo del(17p).

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2019 Mar 7;9(3):32. doi: 10.1038/s41408-019-0191-y.

32.

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma.

Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Kumar SK.

Blood Adv. 2019 Mar 12;3(5):744-750. doi: 10.1182/bloodadvances.2018022806.

33.

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.

Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK.

Leukemia. 2019 May;33(5):1273-1277. doi: 10.1038/s41375-019-0419-7. Epub 2019 Feb 20.

PMID:
30787429
34.

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Kumar SK, Dispenzieri A.

Mayo Clin Proc. 2019 Mar;94(3):472-483. doi: 10.1016/j.mayocp.2018.08.006. Epub 2019 Feb 13. Erratum in: Mayo Clin Proc. 2019 Jun;94(6):1121.

PMID:
30770096
35.

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK.

Br J Haematol. 2019 Apr;185(2):254-260. doi: 10.1111/bjh.15800. Epub 2019 Feb 15.

PMID:
30768679
36.

Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.

Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A.

Leukemia. 2019 May;33(5):1268-1272. doi: 10.1038/s41375-019-0400-5. Epub 2019 Feb 8.

PMID:
30737485
37.

Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.

Goyal G, Lau D, Nagle AM, Vassallo R, Rech KL, Ryu JH, Davidge-Pitts CJ, Tobin WO, Koster MJ, Bennani NN, Shah MV, Liu MC, Go RS; Mayo Clinic Histiocytosis Working Group.

Blood. 2019 Apr 4;133(14):1607-1610. doi: 10.1182/blood-2018-12-893917. Epub 2019 Jan 29. No abstract available.

PMID:
30696619
38.

Comparative analysis of staging systems in AL amyloidosis.

Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z. Epub 2019 Jan 23. No abstract available.

PMID:
30675009
39.

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 Apr;94(4):424-430. doi: 10.1002/ajh.25391. Epub 2019 Jan 8.

PMID:
30592078
40.

Arterial involvement in Erdheim-Chester disease: A retrospective cohort study.

Villatoro-Villar M, Bold MS, Warrington KJ, Crowson CS, Goyal G, Shah M, Go RS, Koster MJ.

Medicine (Baltimore). 2018 Dec;97(49):e13452. doi: 10.1097/MD.0000000000013452.

41.

Immune-mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review.

Durani U, Go RS, Kay NE.

Clin Adv Hematol Oncol. 2018 Oct;16(10):670-676. Review.

PMID:
30543597
42.

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV.

Blood Cancer J. 2018 Dec 11;8(12):125. doi: 10.1038/s41408-018-0163-7.

43.

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.

Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2019 Mar;94(3):306-311. doi: 10.1002/ajh.25365. Epub 2018 Dec 13.

PMID:
30516847
44.

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.

Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.

45.

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.

Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV.

Blood Cancer J. 2018 Nov 15;8(12):116. doi: 10.1038/s41408-018-0140-1.

46.

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.

Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, Gonzalez Velez M, Halfdanarson TR, Molina JR, Hubbard JM, Go RS, Mansfield AS, Adjei AA.

Oncologist. 2019 Jan;24(1):96-102. doi: 10.1634/theoncologist.2017-0687. Epub 2018 Nov 9.

PMID:
30413668
47.

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK.

Leukemia. 2019 Mar;33(3):730-738. doi: 10.1038/s41375-018-0271-1. Epub 2018 Oct 15.

PMID:
30323358
48.

Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome.

Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV.

Mayo Clin Proc. 2018 Oct;93(10):1351-1362. doi: 10.1016/j.mayocp.2018.07.008.

PMID:
30286829
49.

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2019 Feb;33(2):527-531. doi: 10.1038/s41375-018-0258-y. Epub 2018 Sep 26. No abstract available.

PMID:
30258095
50.

Monoclonal Gammopathy of Undetermined Significance: Follow-up Patterns in the United States and Concordance With Clinical Practice Guidelines.

Go RS, Heien HC, Sangaralingham LR, Habermann EB, Shah ND.

Mayo Clin Proc Innov Qual Outcomes. 2017 Aug 2;1(2):161-169. doi: 10.1016/j.mayocpiqo.2017.06.002. eCollection 2017 Sep.

Supplemental Content

Support Center